ECTRIMS 2023 | Safety and efficacy of DMTs after switching from natalizumab

Maya Zeineddine, PharmD, Harley Street Medical Center, Abu Dhabi, United Arab Emirates, discusses a study that compares the efficacy and safety of three alternative disease-modifying therapies (DMTs) – ocrelizumab, fingolimod, and alemtuzumab – following cessation of natalizumab. This transition is considered for patients stable on natalizumab but testing positive for serum JC virus antibodies, aiming to minimize the risk of progressive multifocal leukoencephalopathy, a significant adverse event associated with natalizumab. The primary outcomes include annualized relapse rate, disability progression, and MRI activity after switching to the new DMTs. The study’s focal points are efficacy outcomes, detailing annualized relapse rate, time to the first relapse, disability progression over three and six months, and MRI indicators like new T2 lesions and gadolinium-enhancing lesions on the new DMT regimen. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.